Saundra S Buys

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9154144/publications.pdf

Version: 2024-02-01

81 papers	9,053 citations	101543 36 h-index	58581 82 g-index
85 all docs	85 docs citations	85 times ranked	12152 citing authors

#	Article	IF	Citations
1	Maternal and prenatal factors and age at thelarche in the LEGACY Girls Study cohort: implications for breast cancer risk. International Journal of Epidemiology, 2023, 52, 272-283.	1.9	1
2	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	6.3	19
3	Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	1.6	90
4	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
5	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
6	OUP accepted manuscript. International Journal of Epidemiology, 2022, , .	1.9	0
7	Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). Cancer Prevention Research, 2022, 15, 185-191.	1.5	4
8	Body Mass Index and Mammographic Density in a Multiracial and Multiethnic Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1313-1323.	2.5	3
9	21-gene recurrence score testing utilization among older women from different races: A population-based study. Journal of Geriatric Oncology, 2021, 12, 206-211.	1.0	4
10	Comparing 5-Year and Lifetime Risks of Breast CancerÂusing the Prospective Family Study Cohort. Journal of the National Cancer Institute, 2021, 113, 785-791.	6.3	13
11	Patient Interactions With an Automated Conversational Agent Delivering Pretest Genetics Education: Descriptive Study. Journal of Medical Internet Research, 2021, 23, e29447.	4.3	11
12	A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 2021, 21, 510.	2.6	21
13	A competing risks model with binary time varying covariates for estimation of breast cancer risks in BRCA1 families. Statistical Methods in Medical Research, 2021, 30, 2165-2183.	1.5	2
14	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
15	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102.	4.9	498
16	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. JNCI Cancer Spectrum, 2021, 5, pkab090.	2.9	1
17	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
18	Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results. Journal of the National Cancer Institute, 2020, 112, 418-422.	6.3	1

#	Article	IF	Citations
19	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. Cancer Research, 2020, 80, 116-125.	0.9	37
20	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
21	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
22	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
23	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
24	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	2.5	24
25	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	5.0	41
26	Fiber intake and the risk of head and neck cancer in the prostate, lung, colorectal and ovarian (PLCO) cohort. International Journal of Cancer, 2019, 145, 2342-2348.	5.1	17
27	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
28	Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Research, 2019, 21, 52.	5.0	44
29	Population-based relative risks for specific family history constellations of breast cancer. Cancer Causes and Control, 2019, 30, 581-590.	1.8	7
30	Association of Prepubertal and Adolescent Androgen Concentrations With Timing of Breast Development and Family History of Breast Cancer. JAMA Network Open, 2019, 2, e190083.	5.9	7
31	10-year performance of four models of breast cancer risk: a validation study. Lancet Oncology, The, 2019, 20, 504-517.	10.7	116
32	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
33	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
34	Breast cancer family history and allele-specific DNA methylation in the legacy girls study. Epigenetics, 2018, 13, 240-250.	2.7	10
35	Comparison of methods to assess onset of breast development in the LEGACY Girls Study: methodological considerations for studies of breast cancer. Breast Cancer Research, 2018, 20, 33.	5.0	9
36	The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort. British Journal of Cancer, 2018, 118, 299-306.	6.4	16

#	Article	IF	Citations
37	Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). Breast Cancer Research, 2018, 20, 132.	5.0	51
38	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	2.9	33
39	Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genetics in Medicine, 2017, 19, 30-35.	2.4	53
40	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk â€“ Combined Results from Two Screening Trials. Clinical Cancer Research, 2017, 23, 3628-3637.	7.0	99
41	A study of over 35,000 women with breast cancer tested with a 25â€gene panel of hereditary cancer genes. Cancer, 2017, 123, 1721-1730.	4.1	303
42	A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. Clinical Breast Cancer, 2017, 17, 503-509.	2.4	7
43	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	7.4	1,898
44	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
45	Combating subclonal evolution of resistant cancer phenotypes. Nature Communications, 2017, 8, 1231.	12.8	124
46	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
47	Non-invasive optical spectroscopic monitoring of breast development during puberty. Breast Cancer Research, 2017, 19, 12.	5.0	14
48	Pubertal development in girls by breast cancer family history: the LEGACY girls cohort. Breast Cancer Research, 2017, 19, 69.	5.0	18
49	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
50	Do cancer survivors develop healthier lifestyle behaviors than the cancer-free population in the PLCO study?. Journal of Cancer Survivorship, 2017, 11, 233-245.	2.9	18
51	Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. Journal of Clinical Pharmacology, 2016, 56, 1570-1581.	2.0	17
52	Response: Table 1.. Journal of the National Cancer Institute, 2016, 108, djw173.	6.3	2
53	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
54	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88

#	Article	IF	Citations
55	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2016, 157, 319-327.	2.5	26
56	Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Gynecologic Oncology, 2016, 143, 270-275.	1.4	111
57	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	5.0	42
58	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
59	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
60	Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Molecular Systems Biology, 2016, 12, 860.	7.2	14
61	Evaluation of the relevance and access of EHR-based variables to support personalized medicine in breast cancer. Cogent Medicine, 2016, 3, 1234661.	0.7	1
62	Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). International Journal of Epidemiology, 2016, 45, 683-692.	1.9	48
63	Comparison of Clinical, Maternal, and Self Pubertal Assessments: Implications for Health Studies. Pediatrics, 2016, 138, .	2.1	36
64	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
65	Breast Cancer Risk Perceptions among Relatives of Women with Uninformative Negative BRCA1/2 Test Results: The Moderating Effect of the Amount of Shared Information. Journal of Genetic Counseling, 2016, 25, 258-269.	1.6	21
66	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
67	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
68	31: Impact of Multiple CYP Variants on Tamoxifen Metabolite Concentrations. American Journal of Clinical Pathology, 2015, 143, A015-A015.	0.7	0
69	Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort. British Journal of Cancer, 2015, 113, 809-816.	6.4	99
70	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
71	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
72	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22

#	Article	IF	Citations
73	Expanding Access to BRCA1/2 Genetic Counseling with Telephone Delivery: A Cluster Randomized Trial. Journal of the National Cancer Institute, 2014, 106, dju328-dju328.	6.3	105
74	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
75	Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndromeâ€“Spectrum Cancers. Cancer Discovery, 2014, 4, 804-815.	9.4	44
76	Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine, 2014, 371, 497-506.	27.0	745
77	Analysis of Serial Ovarian Volume Measurements and Incidence of Ovarian Cancer: Implications for Pathogenesis. Journal of the National Cancer Institute, 2014, 106, .	6.3	16
78	Effect of Screening on Ovarian Cancer Mortality. JAMA - Journal of the American Medical Association, 2011, 305, 2295.	7.4	1,080
79	The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Research, 2004, 6, R375-89.	5.0	255
80	The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. Arthritis and Rheumatism, 1999, 42, 1833-1842.	6.7	90
81	Effect of volume and pH on surface receptor number in macrophages. Journal of Cellular Physiology, 1989, 140, 371-378.	4.1	4